Xeris Biopharma Holdings Stock Price, News & Analysis

Xeris Biopharma Holdings (Nasdaq: XERS) has entered a collaboration with Regeneron Pharmaceuticals to utilize its XeriJect™ platform for developing concentrated subcutaneous injections of two undisclosed monoclonal antibodies. The agreement includes an upfront payment and potential milestone payments based on preclinical achievements. Regeneron retains the option to commercially license the Xeris technology and nominate additional molecules for reformulation. XeriJect™ offers ready-to-use, high-drug-loaded suspensions, addressing patient needs in drug delivery. This partnership is a part of Xeris' ongoing collaborations with major biopharmaceutical firms.

Xeris Biopharma Holdings (Nasdaq: XERS) appointed Ricki Fairley to its Board of Directors, expanding the board to nine members as of March 27, 2023. Fairley brings over 35 years of marketing experience, including roles at Johnson & Johnson and Coca-Cola. She is the co-founder and CEO of TOUCH, The Black Breast Cancer Alliance and has a history of advocating for increased participation of Black women in clinical trials. The company's focus remains on developing and commercializing innovative products to enhance patient care.

Xeris Biopharma achieved a record fourth quarter net product revenue of $32.5M, marking a 52% growth compared to Q4 2021. Full-year revenues reached $109.3M, a 38% increase year-over-year on a pro forma basis. The company ended 2022 with $122.0M in cash and achieved $50M in synergies from the Strongbridge acquisition. For 2023, Xeris projects revenues between $135M-$165M and cash utilization from operations of $57M-$77M. The company aims for cash flow breakeven by Q4 2023. Recent collaborations, including with Horizon Therapeutics, further enhance its growth prospects.

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) has announced it will release its fourth-quarter and full-year 2022 financial results on March 8, 2023, before market open. Following this, management will host a conference call and webcast at 8:30 a.m. ET to discuss the outcomes. Xeris focuses on developing innovative biopharmaceutical products, including Gvoke®, Keveyis®, and Recorlev®. The company aims to enhance patient lives through differentiated therapies and has a diverse pipeline leveraging its proprietary formulation sciences, XeriSol™ and XeriJect™.

Xeris Biopharma, Inc. (Nasdaq: XERS) announced its participation in the SVB Securities Global Biopharma Conference 2023, scheduled for February 15, 2023, from 10:40 to 11:10 am ET. Senior management will conduct 1x1 investor meetings and provide a company overview. Investors can access the audio webcast on the company's website. Xeris is focused on developing innovative biopharmaceutical products, including Gvoke® for severe hypoglycemia, Keveyis® for primary periodic paralysis, and Recorlev® for Cushing's syndrome. The company utilizes proprietary formulation platforms, XeriSol™ and XeriJect™, to enhance its product pipeline.

Xeris Biopharma Holdings (Nasdaq: XERS) has received orphan-drug exclusivity for Recorlev® (levoketoconazole) from the FDA, marking it as the first approved treatment for endogenous Cushing’s syndrome. This exclusivity provides Xeris a seven-year market advantage following its December 30, 2021, approval. Recorlev is indicated for adult patients unable to undergo surgery or where surgery has failed. The approval is based on successful Phase 3 trials involving 166 patients, demonstrating significant efficacy in cortisol reduction. Xeris emphasizes its commitment to supporting patients through comprehensive programs like Xeris CareConnection.

Xeris Biopharma Holdings (Nasdaq: XERS) announced that CEO Paul R. Edick will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 12:00 PM PT. Interested parties can access the presentation on the company's investor relations page. Xeris focuses on developing innovative biopharmaceutical products, including Gvoke®, Keveyis®, and Recorlev®. The company also leverages advanced formulation technology platforms, XeriSol™ and XeriJect™, to enhance therapeutic options for patients.

Xeris Biopharma Holdings (Nasdaq: XERS) expects to conclude 2022 with over $120 million in cash and achieve net product revenue at the upper end of its guidance, between $105 million and $110 million. The company experienced strong demand for its products, notably Recorlev and Keveyis, and positive prescription growth for Gvoke. It drew down the final $50 million from its debt facility and secured an upfront payment from a collaboration with Horizon Therapeutics.

Xeris Biopharma Holdings (Nasdaq: XERS) announced plans to initiate a Phase II study in the second half of 2023 for a novel formulation of levothyroxine sodium (SC injection) as replacement therapy for hypothyroidism. This decision follows positive feedback from an FDA Type C meeting regarding the clinical plan for a once-weekly subcutaneous formulation. The Phase II study aims to assess the average dosing and chronic safety data. The company had previously reported positive Phase I data, indicating safety and effective absorption profiles compared to current treatments.